Abstract: The present invention relates to a polybutylene terephthalate resin composition having excellent heat resistance properties and high toughness, comprising 85 to 99.5 parts by mass of a polybutylene terephthalate resin (A) having an intrinsic viscosity (IV) of 1.0 to 1.3 dl/g, 0 to 13 parts by mass of a polyester elastomer (B), and 0.05 to 2 parts by mass of a talc (C) having an average particle size of 5 ?m or less, based on 100 parts by mass in total of components (A), (B) and (C), wherein in the case where the polyester elastomer (B) is contained, the mass ratio of hard segment/soft segment constituting the polyester elastomer (B) is 85/15 to 50/50.

Abstract: The present invention relates to a polybutylene terephthalate resin composition having excellent heat resistance properties and high toughness, comprising 85 to 99.5 parts by mass of a polybutylene terephthalate resin (A) having an intrinsic viscosity (IV) of 1.0 to 1.3 dl/g, 0 to 13 parts by mass of a polyester elastomer (B ), and 0.05 to 2 parts by mass of a talc (C) having an average particle size of 5 ?m or less, based on 100 parts by mass in total of components (A), (B) and (C), wherein in the case where the polyester elastomer (B) is contained, the mass ratio of hard segment/soft segment constituting the polyester elastomer (B) is 85/15 to 50/50.

Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.

Abstract: Disclosed are a Fuc3S4S substituted oligoglycosaminoglycan with a weight-average molecular weight (Mw) of about 4.5-9 kD, a pharmaceutical composition containing the Fuc3S4S substituted oligoglycosaminoglycan, a preparation method thereof and a use thereof in preparing medicines for preventing and/or treating thrombotic diseases.

Abstract: This invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumor activity and lower nervous system toxicity by structurally modification of the parent structure of ?-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumor medicines and medicines used in treatment of tumor diseases in combination of light or radiation therapy.

Abstract: This invention relates to compounds of general formula (I), wherein R1, R2, R3, R4 and R5 are as defined in the specification; intermediates used in their preparation, preparation processes and use thereof. The present invention produces new harmine derivatives with enhanced antitumour activity and lower nervous system toxicity by structurally modification of the parent structure of ?-carboline of harmines at position 1, 2, 3, 7 and 9. The compounds of the present invention can be prepared easily with high yield. They can be used in manufacture of a variety of antitumour medicines and medicines used in treatment of tumour diseases in combination of light or radiation therapy.